Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 18, Issue 4, 2012, Pages 180-184

  Savioli, Cynthia ^a   Ribeiro, Ana Cristina M ^a   Fabri, Gisele Maria Campos ^a   Calich, Ana Luisa ^a   Carvalho, Jozélio ^a   Silva, Clovis A ^a   Viana, Vilma S T ^a   Bonfá, Eloísa ^a   Siqueira, José Tadeu T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

biologic therapy; oral health; periodontal disease; rheumatoid arthritis; tumor necrosis factor

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION; FEMALE; GINGIVA BLEEDING; HUMAN; MALE; MOUTH PLAQUE; PERIODONTAL DISEASE; PERIODONTAL POCKET; PERIODONTIUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; TOOTH CERVIX; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIODONTAL DISEASES; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862191445     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31825828be     Document Type: Article

References (48)

1. Mercado FB, Marshall RI, Bartold PM. Inter-relationships between rheumatoid arthritis and periodontal disease. A review. J Clin Periodontol. 2003;30:761-772.
2. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: a review. J Periodontol. 2005;76(Suppl 11):2066-2074.
3. Modi DK, Chopra VS, Bhau U. Rheumatoid arthritis and periodontitis: biological links and the emergence of dual purpose therapies. Indian J Dent Res. 2009;20:86-90.
4. Dissick A, Redman RS, Jones M, et al. Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol. 2010;81:223-230.
5. Jain A, Batista EL Jr., Serhan C, et al. Role for periodontitis in the progression of lipid deposition in an animal model. Infect Immun. 2003;71:6012-6018
6. Klareskog L, van der Heijde D, de Page J, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet. 2004;363:675-681.
7. Keystone E, Kavanaugh A, Sharp J, et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
8. St Clair E, Desiree M, van der Heijde M. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 2004;50:3432-3443.
9. Nixon R, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med. 2006;26:1237-1254.
10. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
11. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.
12. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol. 2003;74:391-401.
13. Assuma R, Oates T, Cochran D, et al. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol. 1998;160:403-409.
14. Di Paola R, Mazzon E, MuiáC, et al. Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol. 2007;150:286-297.
15. Mayer Y, Balbir-Gurman A, Machtei EE. AntiYtumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. J Periodontol. 2009;80:1414-1420.
16. Pers JO, Saraux A, Pierre R, et al. AntiYTNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontol. 2008;79:1645-1651.
17. Ortiz P, Bissada NF, Palomo L, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol. 2009;80:535-540.
18. Al-Katma MK, Bissada NF, Bordeaux JM, et al. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol. 2007;13:134-137.
19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
20. Ainamo J, Bay I. problems and proposals for recording gingivitis and plaque. Int Dent J. 1975;25:229-235.
21. O'Leary TJ. The periodontal screening examination. J Periodontol. 1967;38:617-624.
22. The American Academy of Periodontology: periodontol record. Ann Periodontol. 1999;4:1-6.
23. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4:1-6.
24. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008;59:1371-1377.
25. van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity store. Ann Rheum Dis. 1990;49:916-920.
26. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal sutudy of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48
27. da Mota Falcão D, Ciconelli RM, Ferraz MB. Translation and cultural adaptation of quality of life questionnaires: an evaluation of methodology. J Rheumatol. 2003;30:379-385.
28. Ferraz MB, Oliveira LM, Araujo PM, et al. Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. J Rheumatol. 1990;17:813-817.
29. Pruijn GJM, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2010;12:203.
30. van der Linden MP, van der Woude D, Ioan-Facsinay A, et al. Value of antiYmodified citrullinated vimentin and third-generation antiYcyclic citrullinated peptide compared with second-generation antiYcyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009;60:2232-2241.
31. Kristensen LE, Kapetanovic MC, Gülfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008; 47:495-499.
32. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70(Suppl 1):i2Yi36.
33. Offenbacher S, Barros SP, Beck JD. Rethinking periodontal inflammation. J Periodontol. 2008;79(Suppl 8):1577-1584.
34. Fernandes EG, Savioli C, Siqueira JT, et al. Oral health and the masticatory system in juvenile systemic lupus erythematosus. Lupus. 2007;16:713-719.
35. Savioli C, Silva CA, Fabri GM, et al. Gingival capillary changes and oral motor weakness in juvenile dermatomyositis. Rheumatology (Oxford). 2010;49:1962-1970.
36. Pihlstrom BL. Periodontal risk assessment, diagnosis and treatment planning. Periodontol 2000. 2001;25:37-58
37. Savage A, Eaton KA, Moles DR, et al. A systematic reviewof definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36:458-467.
38. Mombelli A. Critical issues in periodontal diagnosis. Periodontol 2000. 2005 39 9-12.
39. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and antiYcyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with antiYtumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69-74.
40. Abhishek A, Butt S, Gadsby K, et al. AntiYTNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol. 2010;16:15-18
41. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol. 2009;36:1180-1187.
42. Teng YT, Taylor GW, Scannapieco F, et al. Periodontal health and systemic disorders. J Can Dent Assoc. 2002;68:188-192.
43. Seymour GJ, Taylor JJ. Shouts and whispers: an introduction to immunoregulation in periodontal disease. Periodontol 2000. 2004 35 9-13.
44. Cullinan MP, Ford PJ, Seymour GJ. Periodontal disease and systemic health: current status. Aust Dent J. 2009;54:S62YS69.
45. Pizzo G, Guiglia R, Lo Russo L, et al. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur J Intern Med. 2010;21:496-502.
46. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritisYspecific autoantibodies. J Clin Invest. 1998;101:273-281.
47. Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233:34-54.
48. Hitchon CA, Chandad F, Ferucci ED, et al. Antibodies to Porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol. 2010;37:1105-1112.